Related content

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite

Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

By Shu Xiang   Lin Jie   Wood Christopher G.   Tannir Nizar M.   Wu Xifeng  

Journal of the National Cancer Institute, Vol. 105, Iss. 6, 2013-03 ,pp. : 424-432

Oxford University Press

Access to resources Recommend Favorite

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

By Roca Sophie   Quivy Amandine   Gross-Goupil Marine   Bernhard Jean-Christophe   De Clermont Henri   Ravaud Alain  

Acta Oncologica, Vol. 50, Iss. 7, 2011-10 ,pp. : 1135-1136

Informa Healthcare

Access to resources Recommend Favorite

Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma

By                        

International Journal of Oncology, Vol. 47, Iss. 3, 2015-01 ,pp. : 909-917

Spandidos Publications

Access to resources Recommend Favorite

Targeting mTOR in cancer: renal cell is just a beginning

By Azim Hamdy  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 269-280

Springer Publishing Company

Access to resources Recommend Favorite